¿Tienes alguna pregunta?
Email

TAPCells®

Tapcells

TAPCells
Autologous Dendritic Cells Immunotherapy

TAPCells® has undergone phase I and II clinical trials, demonstrating its safety and long-term clinical effectiveness, prolonging patient survival.

The main advantages of TAPCells® are based on their abundance of diverse tumour antigens, which facilitates the recognition of cancer cells by the immune system. This generates a strong activation of the immune system by stimulating innate immunity.

TAPCells® therapy was developed by a team led by Dr. Flavio Salazar at the Anti-Tumour Immunology Laboratory (ATIL) of the Faculty of Medicine at the University of Chile. Oncobiomed has the exclusive licence to manufacture and distribute TAPCells®.

 

 

Results
+150 patients

Phase I and II trials for malignant melanoma.

+50 patients

Phase I clinical trial for prostate cancer.

Immunological memory

Immunological reactions against tumours prolonging patients’ survival.

Effectiveness and safety

It can be used on different tumours (breast, colon, and others). No adverse side effects were reported.

Contact

Contact

Address
Málaga 85, Las Condes
Santiago, Chile
Phone

+56 9 7753 2325

Email

Please include your phone number or WhatsApp in the message.